Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072975 | 1.00 | PDE4B (0.48) | PDE4BHSD11B1ATMSMN1; SMN2POLB | |
| SCHEMBL2071056 | 0.88 | PDE4B (0.48) | PDE4BHSD11B1SMN1; SMN2POLBMEN1 | |
| SCHEMBL2071055 | 0.88 | PDE4B (0.48) | PDE4BHSD11B1SMN1; SMN2POLBMEN1 | |
| SCHEMBL2070483 | 0.88 | HSD11B1 (0.47) | HSD11B1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL2070481 | 0.88 | HSD11B1 (0.47) | HSD11B1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL2072673 | 0.87 | HSD11B1 (0.44) | HSD11B1SMN1; SMN2POLBNOTUMTSHR | |
| SCHEMBL2072671 | 0.87 | HSD11B1 (0.44) | HSD11B1SMN1; SMN2POLBNOTUMTSHR | |
| SCHEMBL2071679 | 0.87 | POLB (0.52) | PDE4BHSD11B1ATMSMN1; SMN2POLB | |
| SCHEMBL2071682 | 0.87 | POLB (0.52) | PDE4BHSD11B1ATMSMN1; SMN2POLB | |
| SCHEMBL2071484 | 0.86 | HSD11B1 (0.47) | HSD11B1ATMSMN1; SMN2POLBNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897773-B2 | Urea derivatives of tropane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2011-03-01 | — | — | US | disclosed |
| US-20100324084-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-12-23 | — | — | US | disclosed |
| EP-2046791-B1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI AVENTIS (FR) | 2010-03-24 | — | — | EP | disclosed |
| US-20090170894-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | US | disclosed |
| EP-2046791-A2 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Sanofi-Aventis (FR) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008000951-A2 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170894-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | HSD11B1, ADRA1D, HSD17B1 | PDE4B 287/4885HSD11B1 1/4885ATM 4055/4885 |
| US-20100324084-A1 | UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | HSD11B1, ADRA1D, HSD17B1 | PDE4B 287/4885HSD11B1 1/4885ATM 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.